Quick facts
FDA-Approved — Hypoactive Sexual Desire Disorder
FDA-Approved Indication
What is PT-141?
PT-141 is an FDA-approved medication for treating low sexual desire in premenopausal women. Unlike traditional medications that focus on blood flow, PT-141 works directly in the brain. It activates specific pathways in the central nervous system that control sexual arousal and desire. It is designed to be used as needed before sexual activity.
Common Uses
PT-141 is FDA-approved for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
In clinical trials, PT-141 was associated with significant improvements in sexual desire scores and a reduction in distress related to low libido.
Research suggests PT-141 acts on melanocortin receptors in the brain to stimulate sexual arousal pathways.
PT-141 is FDA-approved for use as needed, rather than requiring daily administration like some other treatments for HSDD.
Studies & Clinical Research
PT-141 is an FDA-approved medication that works in the brain to stimulate sexual desire. It activates specific receptors involved in arousal, helping to improve libido in premenopausal women with HSDD.
PT-141 is FDA-approved and was generally well-tolerated in clinical trials. The most common side effects include nausea, flushing, and headache. It is not recommended for individuals with uncontrolled high blood pressure. A licensed provider can help decide if PT-141 is right for you.
In clinical trials, PT-141 was typically administered about 45 minutes before anticipated sexual activity, with effects lasting for several hours. Individual responses may vary.
Yes. PT-141 is a prescription-only, FDA-approved medication. A licensed healthcare provider must review your health history before prescribing PT-141.
Have a question you don’t see answered?
Ready to take the next step?
Find a verified peptide therapy provider or list your practice and connect with patients actively seeking trusted care.